InsiderPulse
Dashboard

KYMR

Kymera Therapeutics, Inc.

Health CareRussell 2000

Kymera Therapeutics, Inc. insider trading

Kymera Therapeutics, Inc. files with the SEC as a Biological Products, (No Diagnostic Substances) company headquartered in Watertown, MA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent KYMR insider transactions

5 insiders traded KYMR on the open market between Jun 29, 2026 and Sep 04, 2026 — 24 sales worth $28.4M, of which 21 were pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$28.4M

21 of 24 on a 10b5-1 plan

Net
−$28.4M
Insiders
5

Open-market purchases (code P) and sales (code S) from Kymera Therapeutics, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every KYMR Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

KYMR insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 15 insiders traded KYMR on the open market: 8 purchases worth $215.3M and 280 sales worth $471.5M, 231 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 2 purchases ($172.5M) and 247 sales ($447.8M), by 11 insiders.

QuarterBoughtSold
Q2 2026—−$370.5M160 sales · 156 on a plan
Q1 2026—−$25.9M47 sales · 26 on a plan
Q4 2025+$172.5M2 buys−$46M38 sales · 24 on a plan
Q3 2025—−$5.4M2 sales · all on a plan
Q2 2025+$42.8M5 buys−$2.9M7 sales · 6 on a plan
Q1 2025—−$630K9 sales
Q4 2024—−$122.5K1 sale · all on a plan
Q3 2024+$461 buy−$20M16 sales · all on a plan
Largest purchase
+$158.1M of KYMR by Baker Felix (Director · 10% Owner) on Dec 11, 2025.
Largest sale
−$89.2M of KYMR by Biotechnology Value Fund II LP (Director) on Jun 26, 2026.

Open-market transactions through Jun 30, 2026most recent first

  • Booth Bruce10b5-1

    Director

    −$2.1M

    Jun 29, 2026

    19,093 sh · $107.76

  • Booth Bruce10b5-1

    Director

    −$1.6M

    Jun 29, 2026

    14,613 sh · $106.63

  • Booth Bruce10b5-1

    Director

    −$578.7K

    Jun 29, 2026

    5,471 sh · $105.78

  • Booth Bruce10b5-1

    Director

    −$325.9K

    Jun 29, 2026

    3,024 sh · $107.76

  • Booth Bruce10b5-1

    Director

    −$247.2K

    Jun 29, 2026

    2,318 sh · $106.63

  • Booth Bruce10b5-1

    Director

    −$132.7K

    Jun 29, 2026

    1,199 sh · $110.67

  • Booth Bruce10b5-1

    Director

    −$89.7K

    Jun 29, 2026

    848 sh · $105.78

  • Booth Bruce10b5-1

    Director

    −$17.5K

    Jun 29, 2026

    157 sh · $111.20

  • Biotechnology Value Fund II LP

    Director

    −$89.2M

    Jun 26, 2026

    837,914 sh · $106.50

  • Biotechnology Value Fund II LP

    Director

    −$66.8M

    Jun 26, 2026

    627,597 sh · $106.50

  • Booth Bruce10b5-1

    Director

    −$25M

    Jun 26, 2026

    231,007 sh · $108.14

  • Biotechnology Value Fund II LP

    Director

    −$12.1M

    Jun 26, 2026

    113,289 sh · $106.50

  • Biotechnology Value Fund II LP

    Director

    −$5.5M

    Jun 26, 2026

    51,858 sh · $106.50

  • Booth Bruce10b5-1

    Director

    −$3.6M

    Jun 26, 2026

    32,624 sh · $109.79

  • Booth Bruce10b5-1

    Director

    −$3.5M

    Jun 26, 2026

    32,402 sh · $108.14

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Kymera Therapeutics, Inc. company record

SEC industry classification
Biological Products, (No Diagnostic Substances)
Headquarters
Watertown, MA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001815442

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought KYMR

What the stock actually did in the 90 days following each open-market purchase

Don't check KYMR — let it ping you

Get told the moment an insider moves on KYMR

Pro watches Kymera Therapeutics, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add KYMR to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track KYMR on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read KYMR insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

LEGNMDGLMRUSNUVLPCVXPTGXRVMDRYTMSMMTSNDXSRRKTGTX
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are KYMR insiders buying or selling?
Between Jun 29, 2026 and Sep 04, 2026, 5 Kymera Therapeutics, Inc. insiders made no open-market purchases and 24 sales worth $28.4M, a net sale of $28.4M. 21 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much KYMR stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 15 Kymera Therapeutics, Inc. insiders made 8 open-market purchases worth $215.3M and 280 sales worth $471.5M. 231 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 2 purchases ($172.5M) and 247 sales ($447.8M). The largest purchase was Baker Felix buying $158.1M on Dec 11, 2025. The largest sale was Biotechnology Value Fund II LP selling $89.2M on Jun 26, 2026.
What was the largest recent KYMR insider trade?
Mainolfi Nello (Chief Executive Officer · Director) sold $6M of KYMR stock on Jul 07, 2026 at about $119.00 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy KYMR shares?
No open-market purchase by a Kymera Therapeutics, Inc. insider appears in the filings from Jun 29, 2026 to Sep 04, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Baker Felix buying $158.1M on Dec 11, 2025.
Where does KYMR insider trading data come from?
From the Form 4 filings Kymera Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.